An open label phase IB/II, non-randomised, dose-finding, safety and tolerability study of Panitumumab, Irinotecan, Trifluridine/Tipiracil in RAS wild-type patients with metastatic colorectal cancer
Phase of Trial: Phase I/II
Latest Information Update: 24 Jul 2018
At a glance
- Drugs Tipiracil/trifluridine (Primary) ; Irinotecan; Panitumumab
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PIT Study
- 17 Jul 2018 Planned initiation date changed from 29 Sep 2017 to 31 Jul 2018.
- 17 Jul 2018 Status changed from not yet recruiting to recruiting.
- 17 Aug 2017 New trial record